UK MHRA issues approval for Formycon aflibercept biosimilar FYB203 (Ahzantive)

News
Article

The biosimilar to aflibercept (Eylea) has already received approval in the EU and US

A phone shows the UK MHRA logo. Image credit: © Ralf – stock.adobe.com

FYB203 is Formycon's second ophthalmic biosimilar to receive approval in the UK. Image credit: © Ralf – stock.adobe.com

Formycon AG announced in a press release that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for FYB203, a biosimilar to aflibercept (Eylea). FYB203 received MHRA approval for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular oedema, macular oedema following retinal vein occlusion and visual impairment due to myopic choroidal neovascularisation.1

The biosimilar will be marketed in the UK under the brand name Ahzantive. In November of 2024, the European Union’s Committee for Medicinal Products for Human Use issued a positive recommendation for Formycon’s marketing authorisation application.2 In January 2025, the European Commission granted approval of the marketing authorisation under the names Ahzantive and Baiama in the EU.

Formycon, based in Munich, Germany, will partner with Teva Pharmaceuticals to commercialise FYB203, as announced earlier this year.3 Teva is already the European commercialisation partner for FYB201, Formycon's biosimilar to ranibizumab (Lucentis), marketed as Ranivisio and Ongavia throughout Europe.

“With the approval of FYB203, our second ophthalmic biosimilar in the UK, we take yet another significant step in making essential ophthalmic therapies more widely available,” said Dr Stefan Glombitza, CEO of Formycon AG.1 “In addition to Ongavia®, our successful ranibizumab biosimilar in the UK, Ahzantive® will provide a new, cost-efficient treatment option for patients with severe retinal diseases, through our strong commercial partner Teva.”

In June 2024, the US Food and Drug Administration (FDA) approved the biosimilar FYB203, also known as aflibercept-mrbb. In a press release at that time, the company stated that FDA approval was rooted in the company's “comprehensive data package” that included “analytical, pre-clinical, clinical and manufacturing data.” Study results showed that FYB203 demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference product in patients with nAMD.2

References

  1. Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE. Press release. Formycon AG. Published February 25, 2025. Accessed February 25, 2025. https://www.formycon.com/en/blog/press-release/formycon-receives-regulatory-approval-in-the-uk-for-fyb203-aflibercept-a-biosimilar-to-eylea-under-the-brand-name-ahzantive/#:~:text=Planegg%2DMartinsried%2C%20Germany%20%E2%80%93%20Formycon,brand%20name%20AHZANTIVE%C2%AE2.
  2. Crago S. CHMP issues positive opinion for marketing authorisation of aflibercept biosimilar FYB203 (Formycon). Ophthalmology Times Europe. Published November 19, 2024. Accessed February 25, 2025. https://europe.ophthalmologytimes.com/view/chmp-issues-positive-opinion-for-marketing-authorisation-of-aflibercept-biosimilar-fyb203-formycon-
  3. Hayes H. Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept). Ophthalmology Times Europe. Updated February 5, 2025. Accessed February 25, 2025. https://europe.ophthalmologytimes.com/view/teva-partners-with-klinge-biopharma-for-commercialisation-of-formycon-s-fyb203-biosimilar-aflibercept-

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.